32. Luft BJ, Hafner R, Korzun AH, et al. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team. N Engl J Med 1993; 329:995-1000. 33. Katlama C, De Wit S, O’Doherty E, et al. Pyrimethamine- clindamycin vs. pyrimethamine-sulfadiazine as acute and long- term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis 1996; 22:268-275. 34. Jacobson JM, Hafner R, Remington J, et al. Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS. AIDS 2001; 15:583-589. 35. Kovacs JA. Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. The NIAID-Clinical Center Intramural AIDS Program. Lancet 1992; 340:637. 36. Benson CA, Kaplan JE, Masur H, et al; CDC; National Institutes of Health; Infectious Diseases Society of America. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations fromCDC, the National Institutes of Health, and the HIVMedicine Association/Infectious Diseases Society of America. [published erratum appears inMMWRMorb Mortal Wkly Rep 2005;54:311]. MMWR RecommRep 2004;53:1–112. 37. DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions inHIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000; 133:447-454. 38. Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother 2006; 57:167-170. 39. Tremont-Lukats IW, Garciarena P, Juarbe R, El-Abassi RN. The immune inflammatory reconstitution syndrome and central nervous system toxoplasmosis. Ann InternMed 2009; 150:656-657. 40. Torres RA, Weinberg W, Stansell J, et al. Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Atovaquone/Toxoplasmic Encephalitis Study Group. Clin Infect Dis 1997; 24:422-429. 41. Katlama C, Mouthon B, Gourdon D, et al. Atovaquone as long- term suppressive therapy for toxoplasmic encephalitis in patients with AIDS andmultiple drug intolerance. Atovaquone Expanded Access Group. AIDS 1996; 10:1107-1112. 42. Kovacs JA, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 2000; 342:1416-1429. Dr. Musa is a fourth-year Resident in Internal Medicine-Pediatrics at LSU School of Medicine in New Orleans. Dr. Martinez is a Professor and Program Director of the Internal Medicine and Emergency Medicine-Internal Medicine training programs at LSU Health Sciences Center in New Orleans. Dr. Hebert is an Associate Professor and Associate ProgramDirector of the Internal Medicine training program at LSU Health Sciences Center in NewOrleans. Dr. Safley is a fourth-year resident in Pathology and Chief Resident at LSU School of Medicine in New Orleans. Dr. Smith is an Assistant Professor at LSU School of Medicine in New Orleans, Department of Radiology. Dr. Lopez is the Richard Vial Professor of Medicine and Vice Chair in the Department of Medicine at LSU School of Medicine in New Orleans, Louisiana.
J La State Med Soc VOL 166 January/February 2014 45
Made with FlippingBook - Online catalogs